

University of Groningen

Dialysis hypotension and vasopressin

Ettema, Esmee M.; Franssen, Casper F. M.

Published in:
Nefrologia

DOI:
[10.3265/Nefrologia.pre2012.Jun.11541](https://doi.org/10.3265/Nefrologia.pre2012.Jun.11541)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2012

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Ettema, E. M., & Franssen, C. F. M. (2012). Dialysis hypotension and vasopressin. *Nefrologia*, 32(5), 679-679. <https://doi.org/10.3265/Nefrologia.pre2012.Jun.11541>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

A) COMENTARIOS A ARTÍCULOS PUBLICADOS

Dialysis hypotension and vasopressin

Nefrología 2012;32(5):679

doi:10.3265/Nefrologia.pre2012.Jun.11541

Dear Editor,

With interest, we read the article by Beladi-Mousavi et al.¹ on the effect of intranasal DDAVP (Desmopressin) for the prevention of dialysis hypotension. The authors showed that, compared with placebo, intranasally administered DDAVP was associated with a significant decrease in the incidence of intradialytic hypotension episodes and higher postdialysis mean arterial blood pressures in 17 hypotension-prone patients. This observation adds evidence to the efficacy of vasopressin analogues for the prevention of dialysis hypotension following the study of Lindberg et al. showing that intranasal lysine-vasopressin increased intradialytic blood pressure in 6 patients with refractory dialysis hypotension.² However, in our opinion, important questions should be answered before intranasal vasopressin analogues can be recommended for the prevention of dialysis hypotension. First, the optimal timing and dosage of intranasal Desmopressin and vasopressin administration must be determined. Therefore, it is important to know which dosage of DDAVP spray (2 puffs) Beladi-Mousavi et al. exactly used in their study. Second, the safety of repetitive intranasal administration of vasopressin analogues should be studied. Did Beladi-Mousavi et al. observe side effects of DDAVP treatment? Finally, future studies should compare the efficacy and safety profile of this treatment with other established measures for the prevention of dialysis hypotension, like cold dialysate and Midrodine administration.

We have some methodological comments on the study by Beladi-Mousavi et al. The authors did not state whether the placebo nasal spray (distilled water) was indistinguishable from the intranasal DDAVP spray. This is relevant to ensure that this was indeed a double-blind study, espe-

cially since all patients were first treated with placebo and then with intranasal DDAVP. Beladi-Mousavi et al. used a rather liberal definition of dialysis hypotension: a fall in systolic blood pressure >10mmHg. Although there is no standardized definition of intradialytic hypotension, recent guidelines propose a more strict definition: a decrease in systolic blood pressure ≥ 20 mmHg or a decrease in MAP by 10mmHg in combination with a clinical event and the need for a nursing intervention.³

Notably, there are alternative vasopressin-related measures for the prevention of dialysis hypotension. Recently, we showed that hemodialysis with the biofeedback system Hemocontrol is associated with a significant increase of plasma vasopressin levels, whereas vasopressin levels did not change during conventional hemodialysis.⁴ Hemocontrol is a technique in which ultrafiltration rate and dialysate conductivity are continuously adjusted in response to blood volume changes. The augmented vasopressin release early during Hemocontrol hemodialysis is likely caused by a higher initial plasma sodium concentration and ultrafiltration rate.

Conflict of interest

The authors declare that there is no conflict of interest associated with this manuscript.

1. Beladi-Mousavi SS, Beladi-Mousavi M, Hayati F, Talebzadeh M. Effect of intranasal DDAVP in prevention of hypotension during hemodialysis. *Nefrología* 2012;32:89-93.
2. Lindberg JS, Copley JB, Melton K, Wade CE, Abrams J, Goode D. Lysine vasopressin in the treatment of refractory hemodialysis-induced hypotension. *Am J Nephrol* 1990;10:269-75.
3. Kooman J, Basci A, Pizzarelli F, Canaud B, Haage P, Fouque D, et al. EBPG guideline on haemodynamic instability. *Nephrol Dial Transplant* 2007;22:ii22-ii44.
4. Ettema EM, Kuipers J, Groen H, Kema IP, de Jong PE, Franssen CF. Vasopressin

release is enhanced by the Hemocontrol biofeedback system and could contribute to better haemodynamic stability during haemodialysis. *Nephrol Dial Transplant* 2012 Feb 7. [Epub ahead of print].

Esmée M. Ettema, Casper F.M. Franssen

Department of Internal Medicine, Division of Nephrology. University Medical Center Groningen. Groningen (Netherlands).

Correspondence: Esmée M. Ettema

Department of Internal Medicine. Division of Nephrology, University Medical Center Groningen, Netherlands. e.m.ettema@umcg.nl

Tratamiento inmunosupresor de nefritis lúpica en insuficiencia renal grave. Sobre el estudio ALMS

Nefrología 2012;32(5):679-80

doi:10.3265/Nefrologia.pre2012.Jun.11527

Sr. Director:

En relación con el Documento de Consenso publicado en esta revista el pasado mes de febrero sobre el diagnóstico y tratamiento de la nefritis lúpica (NL)¹, deseo felicitar al grupo de trabajo por la exquisita labor realizada, a partir de la cual esperamos optimizar el tratamiento de pacientes con esta patología. De su lectura me han surgido dos reflexiones.

1. Houssiau² refiere, en un editorial anexo a la publicación del estudio ALMS³, que, entre los pacientes que recibieron tratamiento de mantenimiento con micofenolato (MMF), los que previamente habían recibido ciclofosfamida (CF) en inducción obtuvieron mejores resultados en la variable resultado principal de la fase de mantenimiento (11 vs. 21% en muerte, duplicación de creatinina basal,